

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Steffen Goletz, Hans Baumeister, Marion Schlangstedt and Ute Schober  
Application No.: 10/568,098 Group: 1633  
371(c) Date: June 20, 2006 Examiner: Leavitt, Maria Gomez  
Confirmation No: 8158  
For: Tumour Cell Lines And Uses Thereof

<b>CERTIFICATE OF MAILING OR TRANSMISSION</b>	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
_____	_____
Date	Signature
_____	
Typed or printed name of person signing certificate	

**COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This letter regarding the reasons for allowance is being filed in response to the Notice of Allowability mailed from the U.S. Patent and Trademark Office on May 12, 2011, in the above-identified, now allowed patent application.

Applicants thank Examiner Leavitt for her availability and discussions during several telephone interviews with their representatives, Anne Collins and Laurence A. Shumway, preceding the Notice of Allowance. The Amendment filed March 29, 2011, the art of record, proposed modifications to the claims were discussed. A final agreement was reached.

In addition, Applicants note the following.

Regarding the Office's statement that "e.g., strong and stable expression of the core glycotope TF after enzymatic desialylation with neuramidase treatment" on page 3 of the Notice

of Allowability, Applicants respectfully reiterate that the cell lines provided by the invention express the TF, MUC1 and glycophorin in the absence of exogenous neuraminidase treatment. *See, inter alia*, page 9 of the Response filed March 29, 2011 and paragraphs 127, 131 and 132 of the published application, U.S. Patent Application Publication No. 2006/0292129.

Also, regarding the Office's statement on page 7 of the Office Action mailed September 29, 2010 that "Figure 1 in the specification evidences that wild type K562 cells before magnetic separation express TF, Tn, GPA, AGPA and MUC1 markers," Applicants note that Figure 1 shows mutagenized K562 cells before separation. *See*, for example Examples 2 and 3, including paragraphs 101, 109, and 128 of the published application, as well as the right column header of Figure 1 "K562 cells before magnetic separation." *See also* paragraphs 25 and 127 of the published application, which note the absence of TF in wild-type K562 cells.

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned. No additional fees are believed to be due with this paper, however, in the event of an error, the Office is authorized to debit Deposit Account No. 08-0380 for any deficiencies or to credit any surplus.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By /Laurence A. Shumway, Reg # 61169/

Laurence A. Shumway

Registration No. 61,169

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Date: August 11, 2011